• Explore /
  • Poster
  • / XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.

XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.

Abstract Poster

Authors

Erika Hamilton

Erika P. Hamilton

Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN

Erika P. Hamilton , Arvind Chaudhry , Alexander I. Spira , Sylvia Adams , Nour Abuhadra , Antonio Giordano , Ritesh Parajuli , Hyo S. Han , Amy M. Weise , Aubri Marchesani , Divya Gupta , Kate Josephs , Kevin Kalinsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT05377996

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS3154)

DOI

10.1200/JCO.2023.41.16_suppl.TPS3154

Abstract #

TPS3154

Poster Bd #

351b

Abstract Disclosures

Similar Posters

First Author: Ashish M. Kamat

First Author: John L. Hays

First Author: Makoto Nishio

First Author: Alexander I. Spira